Dicerna Pharma (DRNA) Misses Q4 EPS by 13c, Beats on Revenues
Note: EPS may not be comparable
Dicerna Pharma (NASDAQ: DRNA) reported Q4 EPS of ($0.90), $0.13 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $1.42 million versus the consensus estimate of $1.36 million.
For earnings history and earnings-related data on Dicerna Pharma (DRNA) click here.